50 years forward: mechanisms of hyperglycaemia-driven diabetic complications

Diabetologia

Volumn 58, Issue 8, 2015, Pages 1708-1714

  Russell, Nicholas D F ^a   Cooper, Mark E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Advanced glycation end products (AGEs); Cardiovascular disease; Diabetic complications; Hyperglycaemia; Mitochondria; Nephropathy; Protein kinase C (PKC); Reactive oxygen species (ROS); Renin angiotensin aldosterone system (RAAS); Retinopathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTILIPEMIC AGENT; GLUCOSE; INSULIN; MICRORNA; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE;

DIABETES MELLITUS; DIABETIC RETINOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EDITORIAL; ENZYME ACTIVATION; EPIGENETICS; GENETIC SUSCEPTIBILITY; GLUCOSE TRANSPORT; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN TREATMENT; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; COMPLICATION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPERGLYCEMIA; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84937523993     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3600-1     Document Type: Editorial

References (22)

1. Fletcher AA, Graham JW (1939) Complications of diabetes mellitus with special reference to cause and prevention. CMAJ 41:566–570
2. Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370:1514–1523
3. Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328
4. Holman RR, Paul SK, Bethel MA et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
5. de Boer IH, Sun W, Gao X et al (2014) Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study. Lancet Diabetes Endocrinol 2:793–800
6. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
7. Zoungas S, Chalmers J, Neal B et al (2014) Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371:1392–1406
8. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591
9. Sima AAF (2010) Encephalopathies: the emerging diabetic complications. Acta Diabetol 47:279–293
10. Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93:137–188
11. Ceriello A, Kilpatrick ES (2013) Glycemic variability: both sides of the story. Diabetes Care 36:S272–S275
12. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P (1995) Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96:1802–1814
13. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
14. Dugan LL, You Y-H, Ali SS et al (2013) AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 123:4888–4899
15. Gray SP, Di Marco E, Okabe J et al (2013) NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127:1888–1902
16. Bennett GJ, Doyle T, Salvemini D (2014) Mitotoxicity in distal symmetrical sensory peripheral neuropathies. Nat Rev Neurol 10:326–336
17. Fried LF, Emanuele N, Zhang JH (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892–1903
18. Winkler EA, Nishida Y, Sagare AP et al (2015) GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. doi:10.1038/nn.3966
19. Cooper ME, El-Osta A (2010) Epigenetics: mechanisms and implications for diabetic complications. Circ Res 107:1403–1413
20. Kato M, Castro NE, Natarajan R (2013) MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med 64:85–94
21. Welsh GI, Hale LJ, Eremina V et al (2010) Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 12:329–340
22. Higgins GC, Coughlan MT (2014) Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol 171:1917–1942